| 前收市價 | 0.2000 |
| 開市 | 0.2000 |
| 買盤 | 0.0000 |
| 賣出價 | 0.6000 |
| 拍板 | 1.00 |
| 到期日 | 2024-11-15 |
| 今日波幅 | 0.2000 - 0.2000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 41 |
BenzingaGossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide
Gossamer Bio Inc (NASDAQ:GOSS) and Italy-based Chiesi Farmaceutici S.p.A, have entered a global collaboration and license agreement to develop and commercialize seralutinib. This global collaboration combines the strengths of both Chiesi and Gossamer to support ongoing work in pulmonary arterial hypertension (PAH) and to accelerate the development of pulmonary hypertension associated with interstitial lung disease (PH-ILD). “Seralutinib is a potential paradigm-shifting therapy in PAH and PH-ILD,
- Reuters
UPDATE 1-Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
Gossamer Bio said on Monday it will collaborate with Italian drugmaker Chiesi Group to develop and commercialize its therapy seralutinib in multiple indications related to high blood pressure due to constriction of lung arteries. The therapy is currently in late-stage development for the treatment of pulmonary arterial hypertension (PAH), which affects about 40,000 people in the United States. Gossamer is to receive $160 million in development reimbursement payment and is eligible to receive up to $146 million in regulatory and $180 million in sales milestones as part of the deal.
Insider Monkey13 Best Biotech Stocks To Buy Under $20
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]
